English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aims/Introduction  It is reported that interfering substances in the blood might influence the value for measurement of active glucagon‐like peptide‐1 ( GLP ‐1) in human plasma. Solid phase extraction ( SPE ) pretreatment is recommended to reduce their influence, but it requires a lot of cost and time. However, there is little investigation about causative inhibitory substances and about methods that can replace solid phase extraction. In the present study, we aimed to seek the candidate of the substances that might interfere with an active  GLP ‐1 enzyme‐linked immunosorbent assay ( ELISA ).    Materials and Methods  Two kinds of active  GLP ‐1  ELISA  kits using different antibodies, plural extraction carriers and elution solutions were used to evaluate the  SPE  method. Active  GLP ‐1 concentration was compared with or without  SPE , and with or without a heterophilic blocking tube.    Results  Active  GLP ‐1 values were often higher without  SPE  compared with those with  SPE  pretreatment. This difference was eliminated by pretreatment with a heterophilic blocking tube or  ELISA  kits that did not use a mouse monoclonal antibody, and was independent of  SPE .    Conclusions  Substances absorbed to a heterophilic blocking tube carrier might interfere with an active  GLP ‐1 immunoassay. Solid‐phase extraction treatment is required for measurement of active  GLP ‐1 by an  ELISA  kit affected by heterophilic antibodies.

journal of diabetes investigation

Solid‐phase extraction treatment is required for measurement of active glucagon‐like peptide‐1 by enzyme‐linked immunosorbent assay kit affected by heterophilic antibodies